CRPC Clinical Trials

2 recruiting

CRPC Trials at a Glance

36 actively recruiting trials for crpc are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Phase 1 with 21 trials, with the heaviest enrollment activity in Omaha, Los Angeles, and Houston. Lead sponsors running crpc studies include Novartis Pharmaceuticals, Blue Earth Therapeutics Ltd, and Acerand Therapeutics (Hong Kong) Limited.

Browse crpc trials by phase

Treatments under study

About CRPC Clinical Trials

Looking for clinical trials for CRPC? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CRPC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CRPC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting
Phase 1Phase 2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled11 locationsNCT07226986
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med LLC48 enrolled4 locationsNCT05283330
Recruiting
Phase 2

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 3

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 1

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer (mCRPC)
Novartis Pharmaceuticals15 enrolled4 locationsNCT07174063
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled2 locationsNCT06844383
Recruiting
Phase 1Phase 2

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 1Phase 2

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and Science99 enrolled1 locationNCT06615752
Recruiting
Phase 1Phase 2

A Study of MHB048C in Patients With Advanced Solid Tumors

Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1Phase 2

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled23 locationsNCT05413850
Recruiting
Phase 1

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited67 enrolled8 locationsNCT06801236
Recruiting
Phase 1Phase 2

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 2

Castrate Resistant Prostate Cancer Enhertu Therapy

Prostate CancerProstate Cancer MetastaticCRPC
Washington D.C. Veterans Affairs Medical Center60 enrolled1 locationNCT06610825
Recruiting
Phase 1Phase 2

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Castration-Resistant Prostate Cancer (CRPC)
Radiopharm Theranostics, Ltd61 enrolled4 locationsNCT07189871
Recruiting
Phase 1

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)
TechnoGenesys, Inc.40 enrolled1 locationNCT06705686
Recruiting
Phase 1

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (CRPC)
ARTBIO Inc.80 enrolled3 locationsNCT07214961
Recruiting
Phase 1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd90 enrolled13 locationsNCT06458712
Recruiting
Phase 1Phase 2

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Ovarian CarcinomaNSCLCSCLC+5 more
Jacobio Pharmaceuticals Co., Ltd.152 enrolled1 locationNCT04686682
Recruiting
Not Applicable

Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity

mCRPC (Metastatic Castration-resistant Prostate Cancer)
Frederic Pouliot45 enrolled1 locationNCT07302763